Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.
Yokohama, Japan - March 14th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and VectorBuilder Inc. have entered into a business alliance. Details in Japanese for local news in Japan. Minaris Regenerative Medicine株式会社（本社：神奈川県横浜市、代表取締役社長 坂東 博人、以下 Minaris）は、VectorBuilder Inc.（本社：Chicago, IL 60609, USA、最高科学責任者 Bruce Lahn, Ph.D.、以下 VectorBuilder）と業務提携を結んだことをお知らせします。 ...
Munich, Germany - November 28th, 2023 - Minaris Regenerative Medicine GmbH, a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry fully owned by Resonac Group, announces the appointment of Hiroto Bando, PhD as CEO of the European operations of Minaris Regenerative Medicine (Minaris) as of November 28, 2023. Hiroto Bando assumes this new role ...
JERSEY CITY, N.J. - September 6th, 2023 - Apprentice.io, leading technology provider for life sciences manufactures, announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, has selected Apprentice’s Tempo Manufacturing Execution System (MES) to digitize its commercial manufacturing in North America and ...
Pleasanton, CA - May 24, 2023 - Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations. Minaris Regenerative Medicine will use Veeva’s unified quality applications to ...
LONDON, UK and MUNICH, GERMANY - February 16, 2023 - LIfT BioSciences, a pioneering pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a leading global contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a development and ...
MUNICH, GERMANY - December 7, 2022 - Minaris Regenerative Medicine is pleased to announce that, effective December 1, 2022, Helmut Lerch, PhD, who joined the company in July of this year as Head, Quality Management for Minaris Regenerative Medicine GmbH (the company’s Germany region) will assume the role of Global Quality Head, succeeding Jacqueline Veivia-Panter. Helmut is an accomplished ...
Munich, Germany, and Stockholm, Sweden - Oct 28, 2022. Mendus AB (“Mendus publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence and Minaris Regenerative Medicine GmbH („Minaris“), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have extended their manufacturing partnership for technology ...
Tokyo, Japan - October 13, 2022. Showa Denko Materials Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President and CEO: Hidehito Takahashi; hereinafter “Showa Denko Materials”) and Kidswell Bio Corporation (Head office: Chuo-ku, Tokyo; President and CEO: Masaharu Tani; hereinafter “Kidswell Bio”) entered into an agreement to enable process development as well as clinical manufacturing...
Allendale, NJ, USA and Yokohama, Japan - October 12, 2022 - Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells (CECSi Cells) for bullous keratopathy novel treatment...